Im not so sure you can use DNDN MC as an accurate comparator. PRR has much more scope in long term, oral gardsil and other mucin 1 expressed cancers, breast is next. As far as I know DNDN is a one product company. I think this very important as US investors will get onto this fact quickly.
Thats if you are long termer of course.
Downside for PRR is they may get bought out before "we" get to realise the real LT value of $10+ and possible future dilution etc for research studies and trials.
Im not so sure you can use DNDN MC as an accurate comparator....
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $493.8M | |||
| Open | High | Low | Value | Volume |
| 34.5¢ | 35.0¢ | 33.5¢ | $724.1K | 2.106M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 60483 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 55452 | 4 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |